AR034483A1 - Formulacion pediatrica de gatifloxacina - Google Patents
Formulacion pediatrica de gatifloxacinaInfo
- Publication number
- AR034483A1 AR034483A1 ARP020102227A ARP020102227A AR034483A1 AR 034483 A1 AR034483 A1 AR 034483A1 AR P020102227 A ARP020102227 A AR P020102227A AR P020102227 A ARP020102227 A AR P020102227A AR 034483 A1 AR034483 A1 AR 034483A1
- Authority
- AR
- Argentina
- Prior art keywords
- gatifloxacin
- precipitate
- taste
- crystalline
- pediatric
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- IJOOSVJZBQQMBV-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrate Chemical compound O.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 IJOOSVJZBQQMBV-UHFFFAOYSA-N 0.000 title 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 abstract 6
- 229960003923 gatifloxacin Drugs 0.000 abstract 6
- 239000002244 precipitate Substances 0.000 abstract 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 235000019640 taste Nutrition 0.000 abstract 2
- 235000021314 Palmitic acid Nutrition 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 235000019658 bitter taste Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940072132 quinolone antibacterials Drugs 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Seasonings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Gatifloxacina antibacteriana de quinolona encubierta adecuadamente en el sabor de modo que la misma pueda ser utilizada para formulaciones pediátricas. Un co-precipitado cristalino de gatifloxacina y uno o ambos del ácido esteárico y ácido palmítico en una relación en peso estrecha encubre de manera efectiva el sabor amargo de la gatifloxacina. El sabor de la gatifloxacina es encubierto efectivamente en la boca y en la suspensión acuosa a través de un ciclo de dosificación total, típicamente de catorce días. La gatifloxacina en los co-precipitados cristalinos va a estar fácilmente disponible para la absorción desde el estómago. Uso de dicho co-precipitado para preparar una composición farmacéutica, especialmente orientada a pediatría, y dicha composición farmacéutica. Se describe también un proceso para formar el co-precipitado de gatifloxacina descripto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29962501P | 2001-06-20 | 2001-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034483A1 true AR034483A1 (es) | 2004-02-25 |
Family
ID=23155586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102227A AR034483A1 (es) | 2001-06-20 | 2002-06-13 | Formulacion pediatrica de gatifloxacina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6589955B2 (es) |
| EP (1) | EP1406572A4 (es) |
| JP (1) | JP4617475B2 (es) |
| KR (1) | KR100888519B1 (es) |
| CN (1) | CN1264514C (es) |
| AR (1) | AR034483A1 (es) |
| AU (1) | AU2002345534B2 (es) |
| BG (1) | BG108444A (es) |
| BR (1) | BR0209692A (es) |
| CA (1) | CA2450742A1 (es) |
| CZ (1) | CZ20033487A3 (es) |
| EE (1) | EE200400018A (es) |
| GE (1) | GEP20053610B (es) |
| HR (1) | HRP20031027A2 (es) |
| HU (1) | HUP0401497A2 (es) |
| IL (1) | IL158863A0 (es) |
| IS (1) | IS7048A (es) |
| MX (1) | MXPA03011451A (es) |
| NO (1) | NO20035605D0 (es) |
| NZ (1) | NZ529611A (es) |
| PE (1) | PE20030126A1 (es) |
| PL (1) | PL366559A1 (es) |
| RU (1) | RU2288218C2 (es) |
| SK (1) | SK14152003A3 (es) |
| TW (1) | TWI224004B (es) |
| UA (1) | UA75656C2 (es) |
| WO (1) | WO2003000175A2 (es) |
| YU (1) | YU100303A (es) |
| ZA (1) | ZA200309173B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383154B2 (en) | 2004-05-11 | 2013-02-26 | Egalet A/S | Swellable dosage form comprising gellan gum |
| US8524735B2 (en) * | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070051418A1 (en) * | 2005-09-02 | 2007-03-08 | Rowles Brian A | Multilayer tubes |
| TW201010708A (en) | 2008-06-02 | 2010-03-16 | Intervet Int Bv | Composition comprising an antibiotic and a corticosteroid |
| HUE038428T2 (hu) | 2008-10-07 | 2018-10-29 | Horizon Orphan Llc | Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében |
| WO2010042549A1 (en) | 2008-10-07 | 2010-04-15 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| PT2473170T (pt) | 2009-09-04 | 2019-08-23 | Horizon Orphan Llc | Utilização de levofloxacina em aerossol para tratamento de fibrose cística |
| CN102397552B (zh) * | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
| CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
| EP2969004A4 (en) | 2013-03-15 | 2016-09-21 | Melinta Therapeutics Inc | METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS |
| US20180118747A1 (en) * | 2017-01-03 | 2018-05-03 | Thermolife International, Llc | Method of isolating theacrine and composition comprising theacrine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO88836A2 (ro) | 1983-10-11 | 1986-03-31 | Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro | Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric |
| JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
| NL193682C (nl) | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| US5405617A (en) | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
| IT1255792B (it) | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
| US5407921A (en) | 1993-07-01 | 1995-04-18 | Kao Corporation | Method for suppressing bitter taste |
| JP3449658B2 (ja) | 1994-12-21 | 2003-09-22 | 杏林製薬株式会社 | 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
| DE19633480A1 (de) | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| CA2227314A1 (en) * | 1997-01-24 | 1998-07-24 | Hoechst Aktiengesellschaft | Preparation of concealed taste preparations of antibacterially active quinolone derivatives |
| GB9702799D0 (en) | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| EP1200129B1 (en) | 1999-07-14 | 2008-10-15 | Schering-Plough Ltd. | Taste masking of oral quinolone liquid preparations using ion exchange resins |
-
2002
- 2002-05-09 US US10/143,487 patent/US6589955B2/en not_active Expired - Lifetime
- 2002-05-10 NZ NZ529611A patent/NZ529611A/en unknown
- 2002-05-10 CN CNB02812409XA patent/CN1264514C/zh not_active Expired - Fee Related
- 2002-05-10 CA CA002450742A patent/CA2450742A1/en not_active Abandoned
- 2002-05-10 EE EEP200400018A patent/EE200400018A/xx unknown
- 2002-05-10 KR KR1020037016647A patent/KR100888519B1/ko not_active IP Right Cessation
- 2002-05-10 GE GE5383A patent/GEP20053610B/en unknown
- 2002-05-10 HU HU0401497A patent/HUP0401497A2/hu unknown
- 2002-05-10 AU AU2002345534A patent/AU2002345534B2/en not_active Ceased
- 2002-05-10 YU YU100303A patent/YU100303A/sh unknown
- 2002-05-10 IL IL15886302A patent/IL158863A0/xx unknown
- 2002-05-10 EP EP02744141A patent/EP1406572A4/en not_active Withdrawn
- 2002-05-10 BR BR0209692-7A patent/BR0209692A/pt not_active IP Right Cessation
- 2002-05-10 WO PCT/US2002/014596 patent/WO2003000175A2/en not_active Application Discontinuation
- 2002-05-10 PL PL02366559A patent/PL366559A1/xx not_active Application Discontinuation
- 2002-05-10 JP JP2003506621A patent/JP4617475B2/ja not_active Expired - Fee Related
- 2002-05-10 CZ CZ20033487A patent/CZ20033487A3/cs unknown
- 2002-05-10 RU RU2003136068/04A patent/RU2288218C2/ru not_active IP Right Cessation
- 2002-05-10 MX MXPA03011451A patent/MXPA03011451A/es active IP Right Grant
- 2002-05-10 SK SK1415-2003A patent/SK14152003A3/sk unknown
- 2002-06-13 AR ARP020102227A patent/AR034483A1/es not_active Application Discontinuation
- 2002-06-14 TW TW091113074A patent/TWI224004B/zh not_active IP Right Cessation
- 2002-06-18 PE PE2002000518A patent/PE20030126A1/es not_active Application Discontinuation
- 2002-10-05 UA UA20031211971A patent/UA75656C2/uk unknown
-
2003
- 2003-11-20 IS IS7048A patent/IS7048A/is unknown
- 2003-11-25 ZA ZA200309173A patent/ZA200309173B/en unknown
- 2003-12-10 HR HR20031027A patent/HRP20031027A2/hr not_active Application Discontinuation
- 2003-12-12 BG BG108444A patent/BG108444A/xx unknown
- 2003-12-16 NO NO20035605A patent/NO20035605D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034483A1 (es) | Formulacion pediatrica de gatifloxacina | |
| ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
| AR038947A1 (es) | Suspension oral de sabor agradable y metodo | |
| EE200300126A (et) | Kinoliini ja kinolinooni derivaadid glutamaatretseptori antagonistidena, nende saamine ja kasutamine ravimite valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| AR045161A1 (es) | Derivados de quinazolina | |
| ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
| ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
| IL161290A0 (en) | Stable composition comprising particles in a frozen aqueous matrix | |
| AR015768A1 (es) | DERIVADOS DE IMIDAZO PIRIDINA QUE INHIBEN LA SECRECIoN DE ÁCIDO GÁSTRICO, COMPOSICIoN FARMACÉUTICA, PROCEDIMIENTOS PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA, USO DE DICHOS DERIVADOS PARA PREPARAR MEDICAMENTOS Y COMPUESTOS INTERMEDIARIOS uTILES EN EL PROCEDIMIENTO PARA LA PREPARACIoN DE DICHOS DE | |
| TR200500745T2 (tr) | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. | |
| ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona | |
| WO2006040112A3 (en) | Taste-masking pharmaceutical compositions | |
| HUP0400250A3 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors, their preparation and their use for preparation of pharmaceutical compositions | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| HUP0000450A2 (hu) | 7-(2-Oxa-5,8-diazabiciklo[4.3.0]non-8-il)-kinolon-karbonsav és -naftiridon-karbonsav-származékok alkalmazása Helicobacter pylori fertőzések, és az ezzel kapcsolatos gyomor-bél megbetegedések gyógyítására szolgáló gyógyszerkészítmények előállítására | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| WO2001047913A3 (de) | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung | |
| ATE410148T1 (de) | Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten | |
| MXPA05009282A (es) | Derivados de anilina sustituidos. | |
| TR200402070T4 (tr) | Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı | |
| UY27339A1 (es) | Formulación pediátrica de gatifloxacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |